Hana Biosciences to Present at Life Sciences Conference Hosted by C.E. Unterberg, Towbin
24 Octobre 2005 - 1:58PM
Business Wire
Hana Biosciences (AMEX: HBX), a South San Francisco-based
biopharmaceutical company focused on advancing cancer care, will
present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences
Conference on Tuesday, Oct. 25, 2005, at 2:20 p.m. The presentation
will take place in Room A at the New York Palace Hotel at 455
Madison Ave., New York, New York. Mark Ahn, Ph.D., president and
CEO of Hana Biosciences, will provide a company overview including
a comprehensive discussion of the company's unique oncology
pipeline which includes Zensana(R), an oral spray version of the
popular antiemetic Zofran with commercialization anticipated in
early 2007. The presentation will also include information on the
promising anti-cancer agent, Talotrexin, and the potentially
powerful radiation sensitizer currently in Phase I clinical trials.
The C.E. Unterberg, Towbin Emerging Life Sciences Conference
features more than 60 emerging leaders in the life science,
diagnostics, med tech, specialty pharmacy and medical device
industries. About Hana Biosciences Hana Biosciences Inc. is a South
San Francisco, Calif.-based biopharmaceutical company that
acquires, develops, and commercializes innovative products to
advance cancer care. The company is committed to creating value by
building a world-class team, accelerating the development of lead
product candidates, expanding its pipeline by being the alliance
partner of choice, and nurturing a unique company culture.
Additional information on Hana Biosciences can be found at
www.hanabiosciences.com. This press release contains
forward-looking statements that involve risks and uncertainties
that could cause Hana's actual results to differ materially from
the anticipated results and expectations expressed in these
forward-looking statements. These statements are based on current
expectations, forecasts and assumptions that are subject to risks
and uncertainties, which could cause actual outcomes and results to
differ materially from these statements. Among other things, there
can be no assurances that any of Hana's development efforts
relating to its product candidates will be successful. Other risks
that may affect forward-looking information contained in this press
release include the possibility of being unable to obtain
regulatory approval of Hana's product candidates, the risk that the
results of clinical trials may not support Hana's claims, Hana's
reliance on third-party researchers to develop its product
candidates and its lack of experience in developing pharmaceutical
products. Additional risks are described in the company's Annual
Report on Form 10-KSB for the year ended Dec. 31, 2004. Hana
assumes no obligation to update these forward-looking statements,
except as required by law.
Hana Biosciences (AMEX:HBX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Hana Biosciences (AMEX:HBX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Hana Biosciences (American Stock Exchange): 0 recent articles
Plus d'articles sur Hana Biosciences Inc.